Investment analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) in a note issued to investors on Saturday. The firm set a “sell” rating on the stock.
Separately, Alliance Global Partners increased their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.
Read Our Latest Stock Analysis on Tonix Pharmaceuticals
Tonix Pharmaceuticals Stock Down 2.1 %
Institutional Trading of Tonix Pharmaceuticals
A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 160.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,770,000 shares of the company’s stock after buying an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned 14.09% of Tonix Pharmaceuticals worth $1,519,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 82.26% of the company’s stock.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Recommended Stories
- Five stocks we like better than Tonix Pharmaceuticals
- What is an Earnings Surprise?
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Stock Market Sectors: What Are They and How Many Are There?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- The 3 Best Fintech Stocks to Buy Now
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.